
    
      The purpose of this study is to demonstrate similar efficacy and safety of GP2017 and
      US-licensed HumiraÂ® in patients with moderate to severe rheumatoid arthritis (RA) with
      inadequate response to Disease modifying anti-rheumatic drugs (DMARDs), including
      methotrexate (MTX).
    
  